Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.67 |
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.67 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 9/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277951 | 1.00 | NPC1 (0.67) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28840317 | 0.82 | FGFR1 (0.59) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8832032 | 0.82 | RAB9A (0.53) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8832009 | 0.82 | PDPK1 (0.68) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4115108 | 0.81 | FGFR1 (0.58) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30561047 | 0.81 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30634854 | 0.81 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL172216 | 0.81 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29714859 | 0.80 | FGFR1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL311148 | 0.80 | FGFR1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | claimed |
| US-5597921-A | ANTITUMOR AGENTS, TREATMENT OF LEUKEMIA | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | claimed |
| EP-0695754-A1 | INDOLO 2,3-b]QUINOXALINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-02-07 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| EP-4543856-A1 | BENZOCARBAZOLE DERIVATIVES AS INHIBITORS OF DRP1 | Asha Therapeutics LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023249965-A1 | BENZOCARBAZOLE DERIVATIVES AS INHIBITORS OF DRP1 | ASHA THERAPEUTICS LLC (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3309608-B1 | DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME | LG CHEMICAL LTD (KR) | 2020-05-27 | — | — | EP | disclosed |
| US-10156670-B2 | Polarizing film having specified zero shear viscosity and yield stress and display device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-12-18 | — | — | US | disclosed |
| EP-0231159-B1 | Indoloquinoxalines with substituents in 6-position containing cyclic groups | LUNDBLAD LEIF (SE) | 1994-08-10 | — | — | EP | disclosed |
| EP-0238459-B1 | SUBSTITUTED INDOLOQUINOXALINES | Lundblad, Leif (SE) | 1992-04-15 | — | — | EP | disclosed |
| US-4990510-A | Viricides, anticancer agents | LEIF LUNDBLAD (BE) | 1991-02-05 | — | — | US | disclosed |
| US-4916124-A | Indoloquinoxalines with substituents in 6-position containing cyclic groups as antiviral agents | Lundblad, Lief (SE) | 1990-04-10 | — | — | US | disclosed |
| EP-0238459-A1 | Substituted indoloquinoxalines | Lundblad, Leif (SE) | 1987-09-23 | — | — | EP | disclosed |
| EP-0231159-A1 | Indoloquinoxalines with substituents in 6-position containing cyclic groups | Lundblad, Leif (SE) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987004436-A1 | SUBSTITUTED INDOLOQUINOXALINES | LUNDBLAD, LEIF (SE) | 1987-07-30 | — | — | WO | disclosed |
| WO-1987004437-A1 | INDOLOQUINOXALINES WITH SUBSTITUENTS IN 6-POSITION CONTAINING CYCLIC GROUPS | LUNDBLAD, LEIF (SE) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | NPC1 4647/4885RAB9A 1478/4885ALDH1A1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.